Histone deacetylase inhibitors in clinical development

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Interest in histone deacetylase inhibitors (HDACIs) as antineoplastic drugs has surged due to their targeted action on cancer signaling pathways.
• Newer generation HDACIs are more potent and demonstrate early efficacy, particularly in hematologic malignancies.

Purpose of the Study:

• To review recent insights into the anticancer mechanisms of HDACIs.
• To explore the combination of HDACIs with other agents for enhanced tumor cell differentiation or apoptosis.
• To discuss the clinical translation of these findings in cancer therapy.

Main Methods:

• Review of recent scientific literature on HDACIs and their anticancer effects.
• Analysis of mechanisms of action, including histone acetylation and other pathways.
• Examination of preclinical and clinical studies involving HDACIs, alone and in combination therapies.

Main Results:

• HDACIs target critical signal transduction, cell cycle, and survival pathways.
• Emerging evidence suggests HDACIs can modulate apoptosis induced by other cytotoxic agents.
• Combination strategies involving HDACIs show promise for promoting tumor cell differentiation and apoptosis.

Conclusions:

• HDACIs represent a significant class of molecularly targeted agents for cancer therapy.
• Their role may extend beyond histone acetylation to modulating apoptosis, especially in combination regimens.
• Clinical translation of HDACIs, particularly newer generations, is advancing, with promising results in specific malignancies.